Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

LY4086940

Stage Phase 2

Sponsor Eli Lilly and Company

Sources

registry, as of 2026-11-03

https://clinicaltrials.gov/study/NCT07890376

A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 460. Conditions Obesity; Overweight. The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condit

ClinicalTrials.gov NCT07890376 protocol and results modules

registry, as of 2026-08-19Stale

https://clinicaltrials.gov/study/NCT06945419

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 219. Conditions Healthy; Overweight; Obesity; Type 2 Diabetes. The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks

ClinicalTrials.gov NCT06945419 protocol and results modules

Studies

A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

Registry NCT07890376

Phase Phase 2

Status Not yet recruiting

Enrollment 460

LY4086940 Dose 1

Comparator placebo

Population Obesity; Overweight

LY4086940 Dose 2

Comparator placebo

Population Obesity; Overweight

LY4086940 Dose 3, Titration Schedule A

Comparator placebo

Population Obesity; Overweight

LY4086940 Dose 3, Titration Schedule B

Comparator placebo

Population Obesity; Overweight

LY4086940 Dose 4

Comparator placebo

Population Obesity; Overweight

LY4086940 Dose 5

Comparator placebo

Population Obesity; Overweight

LY4086940 Dose 6, Titration Schedule A

Comparator placebo

Population Obesity; Overweight

LY4086940 Dose 6, Titration Schedule B

Comparator placebo

Population Obesity; Overweight

LY4086940 Dose 6, Titration Schedule C

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Registry NCT06945419

Phase Phase 1

Status Completed

Enrollment 219

Start 2025-04-23

Primary completion 2026-08-05

Study completion 2026-08-05

Catalyst Primary completion. 2026-08-05. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part A: LY4086940 Single Dose (Healthy Participants)

Comparator placebo

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part A: Placebo Single Dose (Healthy Participants)

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part A: LY4086940 Multiple Dose (Healthy Participants)

Comparator placebo

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part A: Placebo Multiple Dose (Healthy Participants)

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity)

Comparator placebo

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part B: Placebo Multiple Dose (Participants with Overweight or Obesity)

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity)

Comparator placebo

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity)

Comparator placebo

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity)

Population Healthy; Overweight; Obesity; Type 2 Diabetes

Part E (Open-Label): LY4086940 Single Dose (Healthy Participants)

Comparator placebo

Population Healthy; Overweight; Obesity; Type 2 Diabetes